US equities
|
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
META
$630.56
▼-1.88%
NVDA
$216.00
▲+2.39%
AAPL
$343.91
▼-1.10%
SPCX
$146.90
▼-0.40%
MSFT
$532.60
▲+1.54%
AMD
$531.28
▲+2.80%
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
META
$630.56
▼-1.88%
NVDA
$216.00
▲+2.39%
AAPL
$343.91
▼-1.10%
SPCX
$146.90
▼-0.40%
MSFT
$532.60
▲+1.54%
AMD
$531.28
▲+2.80%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Telomir Pharmaceuticals, Inc. - Common Stock
(NQ:
TELO
)
0.9985
+0.0185 (+1.89%)
Delayed Quote
Updated: 3:49 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Telomir Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria
↗
June 18, 2025
Telomir-1 improved cell survival, reduced oxidative stress, and restored mitochondrial balance in preclinical progeria study.
Via
Benzinga
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Breakthrough with Telomir-1 in Wilson’s Disease Model
June 11, 2025
Via
Investor Brand Network
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model
June 11, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Breakthrough in Age-Reversal Model With Telomir-1
June 05, 2025
Via
Investor Brand Network
These stocks are moving in today's pre-market session
↗
June 05, 2025
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.
Via
Chartmill
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
June 05, 2025
Via
ACCESS Newswire
EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder
↗
June 05, 2025
Telomir-1 boosted telomere length, restored weight and muscle, and cut oxidative stress in a preclinical Werner Syndrome animal model.
Via
Benzinga
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) to Pursue Partnerships at BIO 2025 as IND Prep for Telomir-1 Advances
June 02, 2025
Via
Investor Brand Network
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
June 02, 2025
Via
ACCESS Newswire
These stocks that are showing activity before the opening bell on Monday.
↗
June 02, 2025
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
June 02, 2025
Via
Benzinga
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Vision Restoration and Retinal Regeneration in Preclinical AMD Study
May 29, 2025
Via
Investor Brand Network
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints
May 29, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Secures $3M Equity Investment to Advance Age-Reversal Pipeline
May 21, 2025
Via
Investor Brand Network
Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND
May 21, 2025
Via
ACCESS Newswire
EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND
↗
May 21, 2025
Telomir Pharma (NASDAQ: TELO) secured $3M in equity financing from Bayshore Trust, its largest shareholder, at $3 per share (18% premium). It also has a $5M credit line. It has 2 innovative drug...
Via
Benzinga
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Breakthrough Silver(II) Antimicrobial Drug Candidate Telomir-Ag2
May 15, 2025
Via
Investor Brand Network
Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity
May 15, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Preclinical Data Supporting Expansion into Autism and Rare Neurological Disorders
May 07, 2025
Via
Investor Brand Network
Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia
May 07, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Success of Telomir-1 in Prostate Cancer Model
March 19, 2025
Via
Investor Brand Network
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
March 19, 2025
Via
ACCESS Newswire
Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows
↗
March 19, 2025
Telomir-1 shows potential in oncology and age-related diseases, with new findings on its role in tumor suppression and chemotherapy toxicity reduction.
Via
Benzinga
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Success in Age-Reversal Science with Telomir-1
February 26, 2025
Via
Investor Brand Network
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines
February 26, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Stabilizes Silver(II) for Advanced Medical Applications
February 21, 2025
Via
Investor Brand Network
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market
February 21, 2025
Via
ACCESS Newswire
Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration
↗
February 20, 2025
Telomir Pharmaceuticals' Telomir-1 stabilizes Silver(II) for medical use, addressing instability issues in antimicrobial treatments and wound care solutions.
Via
Benzinga
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Promising Preclinical Results for Age-Related Macular Degeneration
February 18, 2025
Via
Investor Brand Network
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)
February 18, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
Next >
